We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Unique Patient Sample Transport Reagents Support Safer and More Reliable COVID Testing

By LabMedica International staff writers
Posted on 22 Sep 2021
A new range of products address a full spectrum of molecular and protein testing challenges made clear by the COVID-19 pandemic and the wildfire growth of the Delta variant.

Thomas Scientific (Swedesboro, NJ, USA) has partnered with Truckee Applied Genomics (TAG; Reno, NV, USA) to distribute its unique patient sample transport reagents. More...
Thomas Scientific has been appointed as the sole distributor for the US and Puerto Rico of TAG regents. The agreement provides an expanded distribution channel to research, diagnostic, and manufacturing customers, including clients in molecular pathology, diagnostic kit development, and variant tracking research labs.

With COVID-19 spread increasing from the Delta variant, demand for rapid antigen protein tests has surged and the need for broader NGS-based variant surveillance has become clear. As the diversity of testing has grown, it has become imperative that resources be designed to accommodate changing needs, while maintaining lab worker safety. One key factor for testing flexibility is enabling patient samples to be sent to any available lab without costly and error-prone cold chain shipping. Another key factor is designing in better safety from collection through lab processing, by inactivating virus before transport. With the growth of non-inactivating antigen tests kits, there is a clear need to develop new kits with reagents that inactivate virus to support safer handling.

Without virus inactivation, lab workers processing antigen tests face safety risks from viral exposure. While toxic guanidine-based virus-killing inactivating transport media (ITM) can preserve nucleic acids and be shipped without a cold chain, they do not work for antigen tests as they can denature proteins and interfere with rapid antigen testing mechanisms. And, for all test types, guanidine-based ITMs have safety and handling concerns as they produce toxic cyanide gas when used with bleach washing steps found in molecular testing processes and platforms.

TAG-NPGM+ and TAG-NGPM patient sample collection reagents contain no guanidine, providing better choices. TAG-NPGM+ rapidly inactivates the virus while preserving both antigen proteins and viral nucleic acids. This means that a patient sample collected in TAG-NGPM+ for an antigen test, could also be sent for a positive verification by a gold-standard rt-PCR test, and banked for NextGen Sequencing (NGS) enabling broader population variant tracking. Research Use Only (RUO) TAG-NGPM+ is a truly universal virus inactivating (safe) collection media that works end-to-end for antigen, rt-PCR and NGS tests, and enables lab staff to safely dispose of samples with common lab bleach.

“TAG is delighted to have Thomas Scientific distribute our products because of their deep technical understanding of the challenges of molecular diagnostics,” said Tian Yu, PhD MBA, VP Product Development at Truckee Applied Genomics. “Along with Thomas Scientific, TAG is meeting the need to improve pandemic preparedness, testing safety, and accuracy, while enabling better and broader variant tracking. And beyond TAG-NGPM+, we are glad to be partnering with Thomas Scientific, to find high-potential new applications for the company's non-crosslinking tissue stabilization reagent TAG-1 for oncology researchers, biotech companies, and innovative research labs to improve liquid biopsy, spatial genomics/transcriptomics, and biomarker development.”

"TAG's sample transport products bring an innovative new chemistry much needed by our molecular diagnostics customers. We see great potential for TAG products to improve the safety and test performance of our clients' labs," added Chad Jenkins, Vice President Thomas Scientific Peak Bio Solutions.

Related Links:

Thomas Scientific
Truckee Applied Genomics


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.